These authors contributed equally to this work.
Sirtuin-6–dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients
Version of Record online: 30 JUL 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 3, pages 1054–1064, September 2013
How to Cite
Marquardt, J. U., Fischer, K., Baus, K., Kashyap, A., Ma, S., Krupp, M., Linke, M., Teufel, A., Zechner, U., Strand, D., Thorgeirsson, S. S., Galle, P. R. and Strand, S. (2013), Sirtuin-6–dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology, 58: 1054–1064. doi: 10.1002/hep.26413
Potential conflict of interest: Nothing to report.
This study was supported by grants from the “Inneruniversitäre Forschungsförderung Stufe 1,” Johannes Gutenberg University, Mainz (to S. S.) and in part by the Forschungszentrum Immunologie, Imaging Core Facility, Johannes Gutenberg University, Mainz (to D. S.).
- Issue online: 29 AUG 2013
- Version of Record online: 30 JUL 2013
- Accepted manuscript online: 23 MAR 2013 03:19AM EST
- Manuscript Accepted: 15 MAR 2013
- Manuscript Received: 2 OCT 2012
Additional Supporting Information may be found in the online version of this article.
Supplemental Figure 1. qRT-PCR validation of the microarray results
Gene expression of selected targets in Sirt6-/- hepatocytes from microarray data in comparison to qRT-PCR. Data are referenced to corresponding Sirt6+/+ hepatocytes. (A) shows the upregulated and (B) downregulated genes based on the microarray analyses results. (C) Corresponding correlation plot indicating a high concordance between both methods. (Pearson correlation r=0.85; P-value =<0.001)
Supplemental Figure 2. Functional networks by Ingenuity Pathway Analysis Software
Functional networks associated with SIRT6 signature were determined using Ingenuity Pathway Analyses Software.
Supplemental Figure 3. SIRT6 signature in other cancers
(A) SIRT6 signature and clinical outcome of cancer patients from different types of cancer; integrative meta-analysis of genomic data from 40 primary tumors using the Oncomine Microarray database. Data are presented as the mean odds ratio ± SD with P < 0.0001. (B) Number of studies with overexpression of SIRT6 signature. The table shows No. of studies in reference to corresponding clinic-pathological features, Threshold (odds ratio): 2.0, Threshold (p-Value): <0.0001.
|hep26413-sup-0004-supptab1.doc||1233K||Supplemental Table 1. Sirt6 gene expression signature.|
|hep26413-sup-0005-supptab2.doc||180K||Supplemental Table 2. Patients at risk.|
|hep26413-sup-0006-supptab3.doc||45K||Supplemental Table 3. Top Gene Sets enriched for SIRT6 signalling was identified by the GSEA Microarray tool.|
|hep26413-sup-0007-supptab4.doc||31K||Supplemental Table 4. Primer sequences.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.